Roche Holding AG
SIX:ROG
FCF Margin
Free Cash Flow Margin
FCF Margin measures the amount of cash generated by a firm as a proportion of revenue. The more free cash flow a company has, the more it can allocate to dividends, paying down debt, and growth opportunities.
FCF Margin Across Competitors
| Country | Company | Market Cap |
FCF Margin |
||
|---|---|---|---|---|---|
| CH |
|
Roche Holding AG
SIX:ROG
|
211.2B CHF |
25%
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
699.1B USD |
-3%
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
4%
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
373.4B USD |
23%
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
2T DKK |
25%
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
184.2B CHF |
28%
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
166.2B GBP |
17%
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
193.3B USD |
27%
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
163.5B USD |
7%
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
133.5B USD |
18%
|
|
| FR |
|
Sanofi SA
PAR:SAN
|
109.7B EUR |
6%
|
Roche Holding AG
Glance View
Roche Holding AG, a titan in the world of healthcare, operates from its headquarters in Basel, Switzerland. Established in 1896, Roche has grown into one of the world's leading pharmaceutical and diagnostics companies, driven by a steadfast commitment to advancing medicine and improving lives. Its unique business model is built on two primary pillars: Pharmaceuticals and Diagnostics. The pharmaceutical division focuses on discovering and developing medicines for cancer, immunology, infectious diseases, ophthalmology, and diseases of the central nervous system. A significant portion of its revenue is generated from innovative oncology drugs, which positions Roche as a global leader in cancer treatment. The company's investment in research and development is notably high, emphasizing its dedication to scientific discovery. On the diagnostics front, Roche continually advances its technologies to enhance disease detection and monitoring. This division creates and sells a wide array of diagnostic products and services, ranging from clinical chemistry and immunoassays to molecular biology and tissue diagnostics. By serving hospitals, research labs, and healthcare professionals, Roche Diagnostics aims to make a crucial impact on patient care and health system efficiency. This dual focus on pharmaceuticals and diagnostics allows Roche to capitalize on synergies between drug development and patient diagnostics, often integrating their advancements to provide more tailored and efficient healthcare solutions. The company's financial strength and strategic innovation are underpinned by its ability to adapt to changing market dynamics, ensuring its place as a stalwart in the global healthcare industry.
See Also
FCF Margin measures the amount of cash generated by a firm as a proportion of revenue. The more free cash flow a company has, the more it can allocate to dividends, paying down debt, and growth opportunities.
Based on Roche Holding AG's most recent financial statements, the company has FCF Margin of 24.9%.
You don't have any saved screeners yet